Bayer says Nexavar-Tarceva trial unsuccessful

(Reuters) – The combination of cancer tablets Tarceva and Nexavar to treat patients with liver cancer failed to improve overall survival rates compared with standard Nexavar treatment in a late-stage Phase III trial, drug companies involved said on Monday. Analysts at brokerage Cheuvreux said the news was a small negative for Bayer AG , the lead partner in the trial, but they left peak sales forecasts for Nexavar unchanged at 971 million euros ($1.18 billion) in 2019. …